696 related articles for article (PubMed ID: 11879256)
1. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
2. The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil in healthy volunteers.
Muirhead GJ; Faulkner S; Harness JA; Taubel J
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):37S-43S. PubMed ID: 11879258
[TBL] [Abstract][Full Text] [Related]
3. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
Muirhead GJ; Wulff MB; Fielding A; Kleinermans D; Buss N
Br J Clin Pharmacol; 2000 Aug; 50(2):99-107. PubMed ID: 10930961
[TBL] [Abstract][Full Text] [Related]
5. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.
Muirhead GJ; Rance DJ; Walker DK; Wastall P
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):13S-20S. PubMed ID: 11879255
[TBL] [Abstract][Full Text] [Related]
6. The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers.
Wilner K; Laboy L; LeBel M
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):31S-36S. PubMed ID: 11879257
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality.
Nichols DJ; Muirhead GJ; Harness JA
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):5S-12S. PubMed ID: 11879254
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
[TBL] [Abstract][Full Text] [Related]
9. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
10. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study.
Sekar V; Lefebvre E; De Marez T; De Pauw M; De Paepe E; Vangeneugden T; Hoetelmans RM
Clin Drug Investig; 2008; 28(8):479-85. PubMed ID: 18598093
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
12. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients.
Merry C; Barry MG; Ryan M; Tjia JF; Hennessy M; Eagling VA; Mulcahy F; Back DJ
AIDS; 1999 Oct; 13(15):F101-7. PubMed ID: 10546851
[TBL] [Abstract][Full Text] [Related]
13. The effects of sildenafil on human sperm function in healthy volunteers.
Purvis K; Muirhead GJ; Harness JA
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):53S-60S. PubMed ID: 11879260
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies.
Tomkinson H; Kemp J; Oliver S; Swaisland H; Taboada M; Morris T
BMC Clin Pharmacol; 2011 Mar; 11():3. PubMed ID: 21414193
[TBL] [Abstract][Full Text] [Related]
16. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man.
Walker DK; Ackland MJ; James GC; Muirhead GJ; Rance DJ; Wastall P; Wright PA
Xenobiotica; 1999 Mar; 29(3):297-310. PubMed ID: 10219969
[TBL] [Abstract][Full Text] [Related]
18. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
19. Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit.
Corrigan B; Feltner DE; Ouellet D; Werth JL; Moton AE; Gibson G
Br J Clin Pharmacol; 2009 Aug; 68(2):174-80. PubMed ID: 19694735
[TBL] [Abstract][Full Text] [Related]
20. An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Baird-Bellaire S; Behrle JA; Parker VD; Patat A; Paul J; Nichols AI
Clin Ther; 2013 Jun; 35(6):782-94. PubMed ID: 23623756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
